Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Table 4 Univariable Kaplan-Meier survival analysis

	OS			RFS
	De, n (%)	MST (95%CI)	P value	Re, n (%)	MRT (95%CI)	P value
Age (years)			0.71			0.97
< 49	79 (80.6)	27.00 (22.12-31.88)		68 (69.4)	27.00 (20.88-33.12)
≥ 49	71 (84.5)	23.00 (19.04-26.96)		56 (66.7)	24.00 (18.84-29.16)
Gender			0.68			0.55
Male	113 (83.7)	26.00 (2299-29.01)		91 (67.4)	24.00 (17.96-30.05)
Female	37 (78.7)	26.00 (21.71-30.29)		33 (70.2)	25.00 (17.96-30.04)
Race			0.76			0.26
Han	74 (83.1)	27.00 (22.55-31.76)		65 (73.0)	25.00 (19.01-30.99)
Others	76 (81.7)	26.00 (21.88-30.81)		59 (63.4)	25.00 (15.63-34.37)
Smoking			0.06			0.01
No	114 (82.6)	24.00 (20.33-27.67)		101 (73.2)	24.00 (18.62-29.38)
Yes	36 (81.8)	27.00 (19.67-34.43)		23 (52.3)	33.00 (15.27-50.74)
Drinking			0.10			0.03
No	110 (81.5)	24.00 (20.17-27.83)		97 (71.9)	24.00 (18.44-29.56)
Yes	40 (85.1)	27.00 (22.53-31.47)		27 (57.4)	30.00 (15.73-44.27)
HBsAg			0.26			0.05
Negative	44 (69.8)	28.00 (24.38-31.62)		34 (54.0)	29.00 (18.01-40.00)
Positive	106 (89.1)	24.00 (19.47-28.53)		90 (75.6)	22.00 (16.52-27.48)
Anti-HCV			0.45			0.88
Negative	123 (82.6)	24.00 (19.69-28.31)		99 (66.4)	24.00 (17.81-30.19)
Positive	27 (81.8)	28.00 (23.80-32.20)		25 (75.8)	28.00 (20.61-35.39)
AFP			1.85 × 10-9			1.03 × 10-6
Negative	44 (68.7)	41.00 (29.46-52.54)		35 (54.7)	40.00 (30.18-49.82)
Positive	106 (89.8)	20.00 (17.24-22.77)		89 (75.4)	17.00 (13.10-20.90)
AFB1 exposure			1.31 × 10-9			9.39 × 10-10
Low	58 (77.3)	36.00 (26.75-45.25)		38 (50.7)	43.00 (33.01-52.99)
High	92 (86.0)	20.00 (17.22-22.78)		86 (80.4)	18.00 (14.25-21.75)
Tumor size			5.52 × 10-8			5.3 × 10-6
≤ 5 cm	37 (66.1)	39.00 (27.27-50.73)		31 (55.4)	40.00 (31.01-48.99)
> 5 cm	113 (89.7)	19.00 (15.84-22.16)		93 (73.8)	16.00 (12.48-19.52)
ES grade			3.82 × 10-4			9.07 × 10-3
Low	75 (79.8)	33.00 (28.08-37.92)		61 (64.9)	30.00 (25.23-34.77)
High	75 (85.2)	20.00 (17.07-22.93)		63 (71.6)	19.00 (13.83-24.17)
TNM stage			7.40 × 10-17			4.47 × 10-11
I	24 (80.0)	45.00 (35.63-54.37)		19 (63.3)	37.00 (28.77-45.23)
II	59 (75.6)	27.00 (23.79-30.21)		47 (60.3)	29.00 (21.89-36.11)
III	67 (90.5)	12.00 (8.63-15.37)		58 (78.4)	10.00 (6.26-13.75)
Liver cirrhosis			0.93			0.43
No	45 (80.4)	27.00 (21.49-32.52)		34 (60.7)	27.00 (21.56-32.44)
Yes	105 (83.3)	25.00 (21.51-28.49)		90 (71.4)	24.00 (19.69-28.31)
MVD			7.60 × 10-11			1.07 × 10-11
Low	68 (75.6)	34.00 (31.65-36.35)		49 (54.4)	36.00 (27.49-44.51)
High	82 (89.1)	15.00 (11.87-18.13)		75 (81.5)	13.00 (9.00-16.01)
PVTT			1.50 × 10-6			9.99 × 10-7
Negative	103 (81.1)	29.00 (24.61-33.39)		80 (63.0)	30.00 (25.71-34.29)
Positive	47 (85.5)	12.00 (7.96-16.04)		44 (80.0)	8.00 (5.09-10.91)
MVI			6.65 × 10-8			1.55 × 10-7
Negative	95 (81.9)	29.00 (24.69-33.31)		73 (62.9)	30.00 (25.90-34.10)
Positive	55 (83.3)	11.00 (6.66-15.34)		51 (77.3)	8.00 (4.38-11.62)
TIMP3			3.91 × 10-11			1.89 × 10-6
LTE	86 (96.6)	18.00 (16.64-21.36)		70 (78.7)	16.00 (12.31-19.69)
HTE	64 (68.8)	36.00 (28.20-43.81)		54 (58.1)	32.00 (22.79-41.21)

De: Death patients; Re: Patients with tumor recurrence; OS: Overall survival; RFS: Recurrence-free survival; HCV: Hepatitis C virus; AFP: Alpha fetoprotein; ES: Edmondson and Steiner; TNM: Tumor node metastasis; MVD: Microvessel density; PVTT: Portal vein tumor thrombus; MVI: Microvessel infiltration; LTE: Low TIMP3 expression; HTE: High TIMP3 expression; AFB1: Aflatoxin B1; MST: Median overall survival time; MRT: Median tumor reoccurrence-free survival time.